A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

Recruiting

I'm Interested

Trial ID: NCT00995150

Age - 16 Years-45 Years Gender - Female Accepting Healthy Volunteers - yes

Purpose

The primary objective of this study is to assess the efficacy of a levonorgestrel-releasing intrauterine system (LNG20) in nulliparous and parous females of child-bearing potential who request long-term, reversible contraception for up to 10 years.

Official Title

A Phase 3, Multi-Center, Open-Label Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

Stanford Investigator(s)

Paul D. Blumenthal, MD, MPH
Paul D. Blumenthal, MD, MPH

Professor of Obstetrics and Gynecology (Gynecology-Family Planning) at the Stanford University Medical Center, Emeritus

Eligibility


Inclusion Criteria:

   - Healthy women requesting contraception

   - 16-35 years old

   - Cohort 36-45 years old

   - Sexually active

Exclusion Criteria:

   - Currently pregnant, pregnant within 4 weeks prior to study entry or planning pregnancy
   within 24 months of study entry

   - Currently breastfeeding

   - Current persistent, abnormal vaginal bleeding

View More
View Less

Intervention(s):

drug: LNG20

drug: Mirena

Recruiting

I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kathryn Batham
650-724-7826

©2024 Stanford Medicine